tradingkey.logo

Nexalin Technology Inc

NXL
0.515USD
-0.105-16.95%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
9.37MMarktkapitalisierung
VerlustKGV TTM

Nexalin Technology Inc

0.515
-0.105-16.95%

mehr Informationen über Nexalin Technology Inc Unternehmen

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Nexalin Technology Inc Informationen

BörsenkürzelNXL
Name des UnternehmensNexalin Technology Inc
IPO-datumSep 16, 2022
CEOWhite (Mark)
Anzahl der mitarbeiter6
WertpapierartOrdinary Share
GeschäftsjahresendeSep 16
Addresse1776 Yorktown
StadtHOUSTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl77056
Telefon18322600222
Websitehttps://nexalin.com
BörsenkürzelNXL
IPO-datumSep 16, 2022
CEOWhite (Mark)

Führungskräfte von Nexalin Technology Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
185.75K
+36459.00%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+6000.00%
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
185.75K
+36459.00%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+6000.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Equipment
52.53K
74.41%
Licensing Fee
10.36K
14.67%
Other
7.71K
10.92%
Nach RegionUSD
Name
Umsatz
Anteil
International Sales
59.48K
84.26%
U.S. Sales
11.11K
15.74%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Equipment
52.53K
74.41%
Licensing Fee
10.36K
14.67%
Other
7.71K
10.92%

Aktionärsstatistik

Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Elson (Marilyn)
8.23%
Hu (Benjamin)
2.02%
White (Mark)
1.66%
Owens (David)
1.00%
The Vanguard Group, Inc.
0.95%
Andere
86.14%
Aktionäre
Aktionäre
Anteil
Elson (Marilyn)
8.23%
Hu (Benjamin)
2.02%
White (Mark)
1.66%
Owens (David)
1.00%
The Vanguard Group, Inc.
0.95%
Andere
86.14%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
13.78%
Investment Advisor
1.59%
Hedge Fund
1.11%
Investment Advisor/Hedge Fund
0.96%
Research Firm
0.16%
Venture Capital
0.06%
Andere
82.35%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
38
722.74K
3.87%
-783.30K
2025Q3
37
1.33M
7.29%
+710.60K
2025Q2
41
2.88M
16.54%
-349.86K
2025Q1
40
2.89M
20.99%
-330.73K
2024Q4
39
2.84M
22.05%
+425.03K
2024Q3
30
2.89M
23.47%
+756.88K
2024Q2
27
1.82M
24.31%
-214.81K
2024Q1
20
1.77M
23.82%
-386.75K
2023Q4
19
1.75M
24.04%
-404.23K
2023Q3
19
1.79M
24.48%
+126.81K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Elson (Marilyn)
1.54M
8.23%
--
--
Jun 04, 2025
Hu (Benjamin)
377.10K
2.02%
+36.46K
+10.70%
Sep 29, 2025
White (Mark)
309.13K
1.66%
--
--
Jun 04, 2025
Owens (David)
185.75K
1%
+36.46K
+24.42%
Sep 29, 2025
The Vanguard Group, Inc.
176.58K
0.95%
+16.70K
+10.45%
Sep 30, 2025
MYDA Advisors LLC
150.00K
0.8%
-650.00K
-81.25%
Sep 30, 2025
Geode Capital Management, L.L.C.
121.82K
0.65%
+5.45K
+4.69%
Sep 30, 2025
Kazden (Alan)
83.13K
0.45%
--
--
Jun 04, 2025
Susquehanna International Group, LLP
62.50K
0.34%
+62.50K
--
Sep 30, 2025
Renaissance Technologies LLC
55.70K
0.3%
+9.36K
+20.19%
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI